{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028081","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.088398+00:00","generated_at":"2026-05-31T20:10:55.425819+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged","bullets":["JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.","Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.","Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.","Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.","UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028081","json":"https://secwatch.observer/filing/0001493152-24-028081.json","markdown":"https://secwatch.observer/filing/0001493152-24-028081.md","text":"https://secwatch.observer/filing/0001493152-24-028081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/0001493152-24-028081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224028081/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:10:55.425819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}